AstraZeneca’s Phase III NSCLC Trial Setback: Re-Evaluating the PD-1 Bispecific Strategy in Advanced Oncology
Executive Overview The landscape of immuno-oncology has long been defined by the pursuit of combination therapies and multi-targeted biologic agents...
